

**From:** [Tripp, Lester](#)  
**To:** [James.Miller@LPNT.net](mailto:James.Miller@LPNT.net)  
**Subject:** Request for additional information in support of Raleigh General Hospital license renewal  
**Date:** Wednesday, January 08, 2014 1:14:00 PM

---

**From:** Lester Tripp  
USNRC Region 1

**To:** James Miller, CNMT  
Raleigh General Hospital

**Re:** Request for Additional Information in Support of NRC License Renewal

**Licensee:** Raleigh General Hospital  
**License No:** 47-18046-01  
**Docket No:** 03014390  
**Control No:** 582147

**Date:** January 8, 2014

Dear Mr. Miller:

This correspondence is in reference to your application dated September 6, 2013, requesting renewal of your NRC License No. 47-18046-01. In order for us to continue our review of your application, we need the following information:

1. Robert M. Cargile, M.D. is listed as an authorized user on your current license, but you did not list his name in the renewal request. Please confirm that it is no longer necessary to list Dr. Cargile on your license.
2. Please describe the areas located above and below areas of use and storage of radioactive material in your nuclear medicine department at 1710 Harper Road, Beckley, West Virginia.
3. You have submitted a facility diagram of your PET/CT facility at 1717 Harper Road, Beckley, West Virginia. From your architectural drawings of PET/CT, it is not clear what areas are above, below and adjacent to areas of storage and use of radioactive materials. Please submit a clear, simplified drawing of PET/CT that shows what areas are above, below and adjacent to areas of storage and use of radioactive materials.
4. Please perform an area survey in and around your PET/CT area, with a patient present who has been administered a PET dosage, to demonstrate that the shielding is adequate to assure that radiation levels in unrestricted areas will not result in doses to individual members of the public in excess of those specified in 10 CFR 20.1301. Please forward a copy of the survey.
5. From your renewal application, it is unclear whether you intend to treat inpatients with greater than 30 mCi of I-131. Please confirm that patients treated with I-131 permitted by 10 CFR 35.300, in dosages greater than 30 mCi,

will be releasable pursuant to 10 CFR 35.75. Otherwise, describe the rooms that will be used to house non-releasable patients. Confirm that the patients will be housed in private rooms with private bathroom facilities. Provide room diagrams including adjacent areas on the same floor, areas above and areas below inpatient rooms. Also provide a description of any shielding and show that adequate steps have been taken to ensure that radiation levels will not result in doses to individuals in excess of those specified in 10 CFR 20.1301.

6. Please confirm that you have developed and will implement and maintain **written** procedures for the safe use of unsealed byproduct material that meet the requirements of 10 CFR 20.1101 and 10 CFR 20.1301.

Current NRC regulations and guidance are included on the NRC's website at [www.nrc.gov](http://www.nrc.gov); select Nuclear Materials; Med, Ind, & Academic Uses; then Licensee Toolkits, see our toolkit index page. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

We will continue our review upon receipt of this information. Please reply to my attention at the Region I Office and refer to Mail Control No. 582147. If you have any technical questions regarding this deficiency letter, please call me at (610) 337-5358. Please have the response to this correspondence signed by David Darden, President/CEO.

In order to continue prompt review of your application, we request that you submit your response to this letter within 30 calendar days from the date of this correspondence.

Lester Tripp  
Health Physicist  
Medical Branch  
Division of Nuclear Materials Safety